Confirmed Objective Response Rate (ORR)

In 184 female patients with HER2+ unresectable or mBC,

ENHERTU monotherapy demonstrated a 60.3% confirmed ORR1,a

ENHERTU monotherapy demonstrated a 60.3% confirmed objective response rate ENHERTU monotherapy demonstrated a 60.3% confirmed objective response rate
ENHERTU anti-tumor activity assessed across these prespecified exploratory patient subgroups2,a,b
Presence of brain metastasesc
With brain
metastases

58% ORR
(n=14/24; 95% CI:
37, 78)
Without brain
metastases

61% ORR
(n=98/160; 95% CI:
53, 69)
HR status
HR+
58% ORR
(n=56/97; 95% CI:
47, 68)
HR-
66% ORR
(n=55/83; 95% CI:
55, 76)
Pertuzumab exposure
Prior
pertuzumab

64% ORR
(n=78/121; 95% CI:
55, 73)
No prior
pertuzumab

54% ORR
(n=34/63; 95% CI:
41, 67)

aORR defined as CR+PR per RECIST v1.1 in the ITT population as evaluated by ICR.1,2

bData based on cut-off date of August 1, 2019.2

cPatients with inactive (asymptomatic and previously treated) brain metastases. Brain lesions were non-target lesions.2

HR, hormone receptor.

Ready to learn more about ENHERTU?